Article Details
Retrieved on: 2024-05-16 19:18:14
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Roche's promising CT-388 for weight loss, placing it within the competitive biopharma landscape dominated by peptide therapeutics like semaglutide and tirzepatide from Novo Nordisk and Eli Lilly.
Article found on: www.biocentury.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here